Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2019 | |
| Cash Flows From Operating Activities | |
| Net Income | -35,836 |
| Depreciation Amortization | 460 |
| Accounts payable and accrued liabilities | 559 |
| Other Working Capital | 212 |
| Other Operating Activity | 1,454 |
| Operating Cash Flow | $-33,151 |
| Cash Flows From Investing Activities | |
| PPE Investments | -836 |
| Investing Cash Flow | $-836 |
| Cash Flows From Financing Activities | |
| Common Stock Issued | 191 |
| Other Financing Activity | 15,278 |
| Financing Cash Flow | $15,469 |
| Beginning Cash Position | 40,585 |
| End Cash Position | 22,067 |
| Net Cash Flow | $-18,518 |
| Free Cash Flow | |
| Operating Cash Flow | -33,151 |
| Capital Expenditure | -840 |
| Free Cash Flow | -33,991 |